BioNTech Financial Statements From 2010 to 2024

Stocks . UK . 
Stock . BioNTech SE
0A3M Stock  USD 119.25  1.31  1.09%   
BioNTech financial statements provide useful quarterly and yearly information to potential BioNTech SE investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on BioNTech financial statements helps investors assess BioNTech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting BioNTech's valuation are summarized below:
Gross Profit
16.1 B
Profit Margin
0.4764
Market Capitalization
32.8 B
Enterprise Value Revenue
3.3144
Revenue
9.2 B
There are over seventy-three available fundamental signals for BioNTech SE, which can be analyzed over time and compared to other ratios. We recommend to validate BioNTech's prevailing fundamental drivers against the all of the trends between 2010 and 2024.

BioNTech Total Revenue

7.48 Billion

Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech's main balance sheet or income statement drivers, such as Interest Expense of 5.3 M, Other Operating Expenses of 385.3 M or EBIT of 14.4 B, as well as many indicators such as . BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.
  
This module can also supplement various BioNTech Technical models . Check out the analysis of BioNTech Correlation against competitors.

BioNTech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Current Liabilities964.9 M540.3 M513.3 M
Slightly volatile
Total Current Liabilities1.5 B2.1 B809.3 M
Slightly volatile
Other Liabilities200.3 M326.5 M214.6 M
Pretty Stable
Accounts Payable371.7 M354 M111.6 M
Slightly volatile
Other Assets300.9 M286.6 M70.6 M
Slightly volatile
Net Receivables3.4 B2.2 B1.7 B
Slightly volatile
Inventory217.8 M357.7 M108.7 M
Slightly volatile
Other Current Assets294.9 M280.9 M75 M
Slightly volatile
Total Current Assets20.5 B19.5 B5.4 B
Slightly volatile
Common Stock238.7 M283.2 M201.4 M
Slightly volatile
Property Plant Equipment628.4 M598.5 M244.7 M
Slightly volatile
Total Assets12.1 B23 B5.5 B
Slightly volatile
Total Stockholder Equity21.3 B20.2 B5.2 B
Slightly volatile
Cash12.2 B11.7 B3 B
Slightly volatile
Non Current Assets Total3.7 B3.5 B798.2 M
Slightly volatile
Good Will380.6 M362.5 M61.6 M
Slightly volatile
Common Stock Shares Outstanding260.6 M237.7 M234.5 M
Slightly volatile
Short Term Investments5.1 B4.9 B715.2 M
Slightly volatile
Non Current Liabilities Total400.6 M689.9 M311 M
Slightly volatile
Total Liabilities2.1 B2.8 B1.1 B
Slightly volatile
Net Invested Capital21.5 B20.5 B5.2 B
Slightly volatile
Capital Stock259.5 M285.9 M217.2 M
Slightly volatile
Net Working Capital9.1 B17.5 B4.1 B
Slightly volatile
Intangible Assets844.3 M804.1 M195.7 M
Slightly volatile
Property Plant And Equipment Net613.2 M971.6 M315.5 M
Slightly volatile
Property Plant And Equipment Gross686.9 M1.2 B372.4 M
Slightly volatile
Long Term Debt154 M191 M215.6 M
Slightly volatile
Short and Long Term Debt40.6 M28.1 M22.3 M
Slightly volatile
Non Current Liabilities Other71.4 M51.9 M204 M
Slightly volatile
Deferred Long Term Liabilities10.9 M12.2 M13.3 M
Slightly volatile

BioNTech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses385.3 M367 M79.4 M
Slightly volatile
Interest Income375.5 M357.6 M72.4 M
Slightly volatile
Selling General Administrative293.8 M557.7 M140.9 M
Slightly volatile
Total Revenue7.5 B3.8 B3.3 B
Slightly volatile
Gross Profit5.8 B3.2 B2.6 B
Slightly volatile
Research Development966.8 M1.8 B492.3 M
Slightly volatile
Cost Of Revenue569.8 M599.8 M650.8 M
Slightly volatile
Total Operating Expenses2.3 B2.9 B1.1 B
Slightly volatile
Reconciled Depreciation192.6 M183.4 M56.3 M
Slightly volatile

BioNTech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation192.6 M183.4 M50.2 M
Slightly volatile
Capital Expenditures740.8 M705.5 M151.1 M
Slightly volatile
End Period Cash Flow12.2 B11.7 B2.9 B
Slightly volatile
Change To Netincome1.5 B1.4 B384.4 M
Slightly volatile
Begin Period Cash Flow14.6 B13.9 B2.3 B
Slightly volatile
Stock Based Compensation66.6 M51.4 M42.8 M
Slightly volatile

BioNTech Fundamental Market Drivers

Forward Price Earnings7.0721

About BioNTech Financial Statements

BioNTech investors utilize fundamental indicators, such as revenue or net income, to predict how BioNTech Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Total Revenue3.8 B7.5 B
Cost Of Revenue599.8 M569.8 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:
How To Invest In BioNTech
Details
Is BioNTech Stock a good investment?
Details
What is BioNTech's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of BioNTech Correlation against competitors.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Altman
Z Score
Details
Intrinsic
Valuation
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY